Ajardy 10 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Empagliflozin |
| Company | Ziska pharmaceuticals ltd |
| Also available as |
Indications
- Adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus
- Reducing the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease
Pharmacology
Empagliflozin is a sodium glucose co-transporter-2 (SGLT-2) inhibitor. It reduces renal threshold for glucose, leading to increased glucose excretion, reduced hyperglycemia, weight loss, and lowered blood pressure.
Dosage & Administration
Recommended dose of Empagliflozin is 10 mg once daily, optionally increased to 25 mg once daily in tolerant patients. Correcting volume depletion before initiation is advised.
Interaction
- Increased urine volume when co-administered with diuretics
- Increased risk of hypoglycemia when co-administered with insulin or insulin secretagogues
- Not recommended to monitor glycemic control with urine glucose tests or 1,5-AG assay when taking SGLT2 inhibitors
Contraindications
Contraindicated in patients with serious hypersensitivity reaction to Empagliflozin or its ingredients, severe renal impairment, end-stage renal disease, or dialysis
Side Effects
- Urinary tract infections
- Female genital mycotic infections
- Dehydration
- Hypotension
- Weakness
- Dizziness
- Increased thirstiness
Pregnancy & Lactation
- Use during pregnancy only if the potential benefit justifies the potential risk to the fetus
- Not recommended when breastfeeding due to unknown excretion in human milk
Precautions & Warnings
Assessment of renal function is recommended prior to initiation, should not be initiated in patients with eGFR less than 45 ml/min/1.73 m^2. No dose adjustment needed in patients with eGFR >= 45 ml/min/1.73 m^2
Overdose Effects
Recommend usual supportive measures in case of overdose, with no specific recommendation on removal through hemodialysis
Therapeutic Class
Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors
Storage Conditions
Keep in a cool & dry place (below 30°C), protected from light & moisture. Keep out of the reach of children
Chemical Structure
- Molecular Formula: C23H27ClO7
- Chemical Structure Image URL: https://medex.com.bd/storage/res/g-res-1275-empagliflozin-chemical-structure-Z3X0mrA6UvgM682Jgp8K.svg
Common Questions about Ajardy 10 mg Tablet
- What is Ajardy 10 mg Tablet?: Ajardy 10 mg Tablet is a SGLT-2 inhibitor which reduces the reabsorption of glucose from the kidney
- What is Ajardy 10 mg Tablet used for?: Ajardy 10 mg Tablet is commonly used to improve glycemic control in adults
- Pregnancy Warnings: Ajardy 10 mg Tablet may be unsafe to use during pregnancy
- Breast-feeding Warnings: Ajardy 10 mg Tablet is probably unsafe to use during breastfeeding
- Effect on Kidney Function: Should be used cautiously in patients with underlying kidney disease
- Effect on Liver Function: No dose adjustment is needed for patients with mild to moderate liver disease
- Quick Tips:
- Used alone or together with other diabetes medicines to control blood sugar and avoid long-term complications
- May cause dehydration and increased urination, so maintain hydration
- May cause hypoglycemia when used with other antidiabetic medicines, alcohol or if meals are delayed or missed
- Can cause genital fungal and/or urinary tract infections, so practice good hygiene
- Monitor blood sugar regularly while taking Ajardy
- Inform the doctor of constant dizziness, joint pain, cold-like symptoms, or unexplained nausea/vomiting